The Patent Finder

Tanabe Pharma Corporation

34 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Mitsubishi Tanabe Pharma Corporation (to 2026)

6
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 6 to 25, 2026 · next Dec 6
  • 1 fee due Feb 28, 2027
    The maintenance fee for Analysis Method of 3-Methyl-1-Phenyl-2-Pyrazolin-5-ONE Active Pharmaceutical Ingredient, Treatment for Amyotrophic Lateral Sclerosis, Inhibition of Progression of Amyotrophic Lateral Sclerosis, and Method of Producing Medicament Containing 3-Methyl-1-Phenyl-2-Pyrazolin-5-ONE Active Pharmaceutical Ingredient (US 11,740,219) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 1 fee due Oct 30, 2027
    The maintenance fee for Compounds and Their Use (US 11,970,463) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,943,788Glucopyranoside Compound
In force
 · High confidence
In forceHigh confidence
US 8,513,202Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,198,287Substituted Heteroaryl Pyridopyrimidone Derivatives
In force
 · High confidence
In forceHigh confidence
US 9,956,203Plastic container comprising cyclic polyolefin layer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,943,582Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,809,304Amine compound and use thereof for medical purposes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,655,852Tablets containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,024,009Process for the Preparation of Compounds Useful as Inhibitors of SGLT
In force
 · High confidence
In forceHigh confidence
US 10,004,720Agent for preventing and/or treating ophthalmologic diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,065,972Bicyclic or tricyclic heterocyclic compound
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 34 patents shown.
Pro members see all 34.
Pro members: see all 34 patents
Also on record, not counted in the 34: 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited